Literature DB >> 33523107

Data-driven definitions for active and structural MRI lesions in the sacroiliac joint in spondyloarthritis and their predictive utility.

Walter P Maksymowych1,2, Robert G Lambert3,4, Xenofon Baraliakos5, Ulrich Weber6,7, Pedro M Machado8,9,10, Susanne J Pedersen11, Manouk de Hooge12,13, Joachim Sieper14, Stephanie Wichuk1, Denis Poddubnyy14, Martin Rudwaleit15,16, Désirée van der Heijde17, Robert Landewe18,19, Iris Eshed20, Mikkel Ostergaard11,21.   

Abstract

OBJECTIVES: To determine quantitative SI joint MRI lesion cut-offs that optimally define a positive MRI for inflammatory and structural lesions typical of axial SpA (axSpA) and that predict clinical diagnosis.
METHODS: The Assessment of SpondyloArthritis international Society (ASAS) MRI group assessed MRIs from the ASAS Classification Cohort in two reading exercises where (A) 169 cases and 7 central readers; (B) 107 cases and 8 central readers. We calculated sensitivity/specificity for the number of SI joint quadrants or slices with bone marrow oedema (BME), erosion, fat lesion, where a majority of central readers had high confidence there was a definite active or structural lesion. Cut-offs with ≥95% specificity were analysed for their predictive utility for follow-up rheumatologist diagnosis of axSpA by calculating positive/negative predictive values (PPVs/NPVs) and selecting cut-offs with PPV ≥ 95%.
RESULTS: Active or structural lesions typical of axSpA on MRI had PPVs ≥ 95% for clinical diagnosis of axSpA. Cut-offs that best reflected a definite active lesion typical of axSpA were either ≥4 SI joint quadrants with BME at any location or at the same location in ≥3 consecutive slices. For definite structural lesion, the optimal cut-offs were any one of ≥3 SI joint quadrants with erosion or ≥5 with fat lesions, erosion at the same location for ≥2 consecutive slices, fat lesions at the same location for ≥3 consecutive slices, or presence of a deep (i.e. >1 cm depth) fat lesion.
CONCLUSION: We propose cut-offs for definite active and structural lesions typical of axSpA that have high PPVs for a long-term clinical diagnosis of axSpA for application in disease classification and clinical research.
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  definitions; magnetic resonance imaging; predictive validity; sacroiliac joint; spondyloarthritis

Mesh:

Year:  2021        PMID: 33523107     DOI: 10.1093/rheumatology/keab099

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  10 in total

Review 1.  Improving the design of RCTs in non-radiographic axial spondyloarthritis.

Authors:  Walter P Maksymowych; Robert G W Lambert; Liron Caplan; Filip E van den Bosch; Mikkel Østergaard
Journal:  Nat Rev Rheumatol       Date:  2022-05-13       Impact factor: 32.286

Review 2.  MRI in axial spondyloarthritis: understanding an 'ASAS-positive MRI' and the ASAS classification criteria.

Authors:  Torsten Diekhoff; Robert Lambert; Kay Geert Hermann
Journal:  Skeletal Radiol       Date:  2022-02-23       Impact factor: 2.128

3.  Australian Consensus Statements for the Assessment and Management of Non-radiographic Axial Spondyloarthritis.

Authors:  Steven L Truong; Tim McEwan; Paul Bird; Irwin Lim; Nivene F Saad; Lionel Schachna; Andrew L Taylor; Philip C Robinson
Journal:  Rheumatol Ther       Date:  2021-12-28

Review 4.  A glance into the future of diagnosis and treatment of spondyloarthritis.

Authors:  Victoria Navarro-Compán; Joerg Ermann; Denis Poddubnyy
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-07-22       Impact factor: 3.625

5.  Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial.

Authors:  Dafna D Gladman; Philip J Mease; Paul Bird; Enrique R Soriano; Soumya D Chakravarty; May Shawi; Stephen Xu; Sean T Quinn; Cinty Gong; Evan Leibowitz; Denis Poddubnyy; Lai-Shan Tam; Philip S Helliwell; Arthur Kavanaugh; Atul Deodhar; Mikkel Østergaard; Xenofon Baraliakos
Journal:  Trials       Date:  2022-09-05       Impact factor: 2.728

6.  Frequency and anatomic distribution of magnetic resonance imaging lesions in the sacroiliac joints of spondyloarthritis and non-spondyloarthritis patients.

Authors:  Sophie Hecquet; Jean-Philippe Lustig; Frank Verhoeven; Mickaël Chouk; Sébastien Aubry; Daniel Wendling; Clément Prati
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-09-05       Impact factor: 3.625

7.  Choose wisely: imaging for diagnosis of axial spondyloarthritis.

Authors:  Torsten Diekhoff; Iris Eshed; Felix Radny; Katharina Ziegeler; Fabian Proft; Juliane Greese; Dominik Deppe; Robert Biesen; Kay Geert Hermann; Denis Poddubnyy
Journal:  Ann Rheum Dis       Date:  2021-05-28       Impact factor: 19.103

8.  What amount of structural damage defines sacroiliitis: a CT study.

Authors:  Kay Geert A Hermann; Katharina Ziegeler; Virginie Kreutzinger; Denis Poddubnyy; Fabian Proft; Dominik Deppe; Juliane Greese; Joachim Sieper; Torsten Diekhoff
Journal:  RMD Open       Date:  2022-01

9.  Current differentiation between radiographic and non-radiographic axial spondyloarthritis is of limited benefit for prediction of important clinical outcomes: data from a large, prospective, observational cohort.

Authors:  Adrian Ciurea; Seraphina Kissling; Kristina Bürki; Xenofon Baraliakos; Manouk de Hooge; Monika Hebeisen; Eleftherios Papagiannoulis; Pascale Exer; René Bräm; Michael J Nissen; Burkhard Möller; Diego Kyburz; Michael Andor; Oliver Distler; Almut Scherer; Raphael Micheroli
Journal:  RMD Open       Date:  2022-02

Review 10.  Differentiating nonradiographic axial spondyloarthritis from its mimics: a narrative review.

Authors:  Philip Mease; Atul Deodhar
Journal:  BMC Musculoskelet Disord       Date:  2022-03-12       Impact factor: 2.362

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.